Subtopic Deep Dive

S100 Proteins in Cancer Progression
Research Guide

What is S100 Proteins in Cancer Progression?

S100 proteins are calcium-binding proteins that promote cancer progression through extracellular signaling, inflammation, and interactions with receptors like RAGE in tumor microenvironments.

Specific S100 family members such as S100A8/A9 and S100A4 drive tumor growth, invasion, and metastasis by regulating myeloid-derived suppressor cells and chronic inflammation (Sinha et al., 2008; Wang et al., 2018). These proteins act as damage-associated molecular patterns (DAMPs) amplifying proinflammatory responses in cancer (Schaefer, 2014). Over 10 key papers from 2003-2022 detail their roles, with foundational works exceeding 600 citations each.

Curated Papers

Key Challenges

Why It Matters

S100 proteins contribute to tumor progression by recruiting immunosuppressive cells, enabling metastasis in cancers like breast and lung (Sinha et al., 2008; Sparvero et al., 2009). Their interaction with RAGE promotes inflammation-driven oncogenesis, positioning them as biomarkers for poor prognosis (Donato, 2003). Targeting S100-RAGE signaling offers therapeutic potential, as shown in preclinical models of myeloid suppression and astrogliosis-linked cancers (Zamanian et al., 2012; Srikrishna et al., 2008).

Key Research Challenges

Heterogeneity of S100 Expression

S100 proteins show variable expression across cancer types, complicating biomarker development (Donato, 2003). Profiling studies reveal tissue-specific roles, requiring integrated genomic data (Zamanian et al., 2012). Distinguishing causal from correlative effects remains unresolved (Schaefer, 2014).

Deciphering Receptor Interactions

S100 proteins bind multiple receptors like RAGE and TLRs, with unclear signaling hierarchies in tumors (Sparvero et al., 2009; Yu et al., 2010). Calcium-dependent binding affinities vary, hindering targeted inhibition (Santamaria-Kisiel et al., 2006). Functional redundancy challenges selective blockade (Wang et al., 2018).

Translating to Therapies

Despite proinflammatory roles, inhibiting S100A8/A9 risks disrupting homeostasis (Sinha et al., 2008). Clinical trials lack due to poor understanding of intracellular vs. extracellular functions (Donato, 2003). Validating targets in metastasis models is needed (Chavakis et al., 2003).

Essential Papers

Genomic Analysis of Reactive Astrogliosis

Jennifer Zamanian, Lijun Xu, Lynette C. Foo et al. · 2012 · Journal of Neuroscience · 2.4K citations

Reactive astrogliosis is characterized by a profound change in astrocyte phenotype in response to all CNS injuries and diseases. To better understand the reactive astrocyte state, we used Affymetri...

S100A8/A9 in Inflammation

Siwen Wang, Rui Song, Ziyi Wang et al. · 2018 · Frontiers in Immunology · 1.4K citations

S100A8 and S100A9 (also known as MRP8 and MRP14, respectively) are Ca<sup>2+</sup> binding proteins belonging to the S100 family. They often exist in the form of heterodimer, while homodimer exists...

Intracellular and extracellular roles of S100 proteins

Rosario Donato · 2003 · Microscopy Research and Technique · 976 citations

Abstract S100, a multigenic family of non‐ubiquitous Ca 2+ ‐modulated proteins of the EF‐hand type expressed in vertebrates exclusively, has been implicated in intracellular and extracellular regul...

Blood GFAP as an emerging biomarker in brain and spinal cord disorders

Ahmed Abdelhak, Matteo Foschi, Samir Abu‐Rumeileh et al. · 2022 · Nature Reviews Neurology · 735 citations

Proinflammatory S100 Proteins Regulate the Accumulation of Myeloid-Derived Suppressor Cells

Pratima Sinha, Chinonyerem Okoro, Dirk Foell et al. · 2008 · The Journal of Immunology · 703 citations

Abstract Chronic inflammation is a complex process that promotes carcinogenesis and tumor progression; however, the mechanisms by which specific inflammatory mediators contribute to tumor growth re...

RAGE (Receptor for Advanced Glycation Endproducts), RAGE Ligands, and their role in Cancer and Inflammation

Louis J. Sparvero, Denise Asafu‐Adjei, Rui Kang et al. · 2009 · Journal of Translational Medicine · 615 citations

Abstract The Receptor for Advanced Glycation Endproducts [RAGE] is an evolutionarily recent member of the immunoglobulin super-family, encoded in the Class III region of the major histocompatabilit...

Complexity of Danger: The Diverse Nature of Damage-associated Molecular Patterns

Liliana Schaefer · 2014 · Journal of Biological Chemistry · 597 citations

Reading Guide

Foundational Papers

Start with Donato (2003) for S100 basics (976 citations), then Sinha et al. (2008) for cancer inflammation links (703 citations), followed by Sparvero et al. (2009) on RAGE signaling (615 citations).

Recent Advances

Wang et al. (2018) on S100A8/A9 mechanisms (1363 citations); Abdelhak et al. (2022) for biomarker extensions (735 citations).

Core Methods

Affymetrix GeneChip for expression (Zamanian et al., 2012); co-immunoprecipitation for interactions (Chavakis et al., 2003); heterodimer stability assays (Wang et al., 2018).

How PapersFlow Helps You Research S100 Proteins in Cancer Progression

Discover & Search

PapersFlow's Research Agent uses searchPapers and citationGraph to map S100-RAGE-cancer links from Sinha et al. (2008), revealing 700+ citations to myeloid suppressor papers. exaSearch uncovers niche reviews on S100A8/A9 in tumors, while findSimilarPapers expands from Sparvero et al. (2009) to 615-cited inflammation studies.

Analyze & Verify

Analysis Agent employs readPaperContent on Zamanian et al. (2012) to extract S100 expression in astrogliosis, then verifyResponse with CoVe checks claims against 2377 citations. runPythonAnalysis processes gene expression data via pandas for S100 upregulation stats in cancer datasets, with GRADE scoring evidence strength for therapeutic claims.

Synthesize & Write

Synthesis Agent detects gaps in S100 therapeutic targeting post-Schaefer (2014), flagging contradictions in RAGE roles. Writing Agent uses latexEditText and latexSyncCitations to draft reviews citing Donato (2003), with latexCompile generating figures and exportMermaid visualizing signaling pathways.

Use Cases

"Analyze S100A8/A9 expression data from cancer genomics datasets"

Research Agent → searchPapers('S100A8 cancer genomics') → Analysis Agent → runPythonAnalysis(pandas on Zamanian et al. 2012 data) → matplotlib heatmaps of upregulation in tumors.

"Write a LaTeX review on S100-RAGE in metastasis"

Synthesis Agent → gap detection on Sparvero et al. (2009) → Writing Agent → latexEditText(structured sections) → latexSyncCitations(10 papers) → latexCompile(PDF with diagrams).

"Find code for S100 protein interaction simulations"

Research Agent → paperExtractUrls(Santamaria-Kisiel et al. 2006) → Code Discovery → paperFindGithubRepo → githubRepoInspect → exportPython scripts for calcium-binding models.

Automated Workflows

Deep Research workflow scans 50+ S100 papers via citationGraph from Sinha et al. (2008), producing structured reports on cancer progression roles with GRADE scores. DeepScan applies 7-step verification to Wang et al. (2018) claims on inflammation, checkpointing RAGE interactions. Theorizer generates hypotheses on S100A4 metastasis from Donato (2003) and Sparvero (2009) patterns.

Try Doxa for S100 Proteins in Cancer Progression Research

Frequently Asked Questions

What defines S100 proteins in cancer progression?

S100 proteins act as extracellular DAMPs promoting inflammation, myeloid suppressor cell accumulation, and metastasis via RAGE and TLRs (Sinha et al., 2008; Sparvero et al., 2009).

What are key methods studying S100 in tumors?

GeneChip profiling identifies S100 upregulation in reactive states (Zamanian et al., 2012); binding assays reveal calcium-dependent interactions (Santamaria-Kisiel et al., 2006).

What are foundational papers?

Donato (2003, 976 citations) details intracellular/extracellular roles; Sinha et al. (2008, 703 citations) links S100 to tumor immunosuppression; Sparvero et al. (2009, 615 citations) covers RAGE in cancer.

What open problems exist?

Selective inhibition without homeostasis disruption; clarifying S100 isoform specificity in metastasis; validating biomarkers in clinical cohorts (Schaefer, 2014; Wang et al., 2018).